Get our comprehensive guide to direct listings, an increasingly common alternative to a traditional IPO. Download Now

Westicke Partners

Close

International Biotech: Accessing the U.S. Capital Markets in a Post-COVID-19 World

Through the coronavirus pandemic, biotech companies have continued to innovate and are turning U.S. capital markets to finance their vision and innovation.

International BiotechnologyInternational Biotech: Accessing the U.S. Capital Markets in a Post-COVID-19 World

July 2020 – Biotech innovations are continuing to advance during the coronavirus pandemic — and many companies are now turning to U.S. capital markets for financing. During this call, a panel of capital markets and biotech experts discussed developments in today’s rapidly changing environment.

Topics covered include:

  • The latest capital markets updates
  • Strategies for outreach to the world’s most sophisticated investors
  • Other issues impacting biotech IPOs, including the upcoming election and an increase in SPAC transactions

Click to view the webinar

Thinking of taking your company public?

Our comprehensive eBook, Westwicke Insider’s Guide to Going Public, takes you all the way through the process, from a year before your IPO to a year after.

Our Locations